We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Clarifies Requirements for Heart Failure Studies
EMA Clarifies Requirements for Heart Failure Studies
The European Medicines Agency released final guidance June 10 on the primary and secondary endpoints sponsors should use to evaluate drugs to treat acute heart failure — along with recommendations on designing and conducting such studies in children.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor